Premium
Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double‐blind randomised trial
Author(s) -
Attilakos G,
Psaroudakis D,
Ash J,
Buchanan R,
Winter C,
Donald F,
Hunt LP,
Draycott T
Publication year - 2010
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2010.02585.x
Subject(s) - medicine , caesarean section , obstetrics , oxytocin , placental abruption , placenta previa , uterotonic , perioperative , obstetrics and gynaecology , randomized controlled trial , gynecology , pregnancy , gestation , anesthesia , placenta , surgery , fetus , genetics , biology
Please cite this paper as: Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter C, Donald F, Hunt L, Draycott T. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double‐blind randomised trial. BJOG 2010;117:929–936. Objective To compare the effectiveness of carbetocin and oxytocin when they are administered after caesarean section for prevention of postpartum haemorrhage (PPH). Study design Double‐blind randomised single centre study (1:1 ratio). Setting Teaching hospital in Bristol, UK with 6000 deliveries per annum. Population Women at term undergoing elective or emergency caesarean section under regional anaesthesia, excluding women with placenta praevia, multiple gestation and placental abruption. Methods Women were randomised to receive either carbetocin 100 μg or oxytocin 5 IU intravenously after the delivery of the baby. Perioperative care was otherwise normal and use of additional oxytocics was at the discretion of the operating obstetrician. Analysis was by intention to treat. Primary outcome measure The proportion of women in each arm of the trial that needed additional pharmacological oxytocic interventions. Results Significantly more women needed additional oxytocics in the oxytocin group (45.5% versus 33.5%, Relative risk 0.74, 95% CI 0.57–0.95). The majority of women had oxytocin infusions. There were no significant differences in the secondary outcomes, including major PPH, blood transfusions and fall in haemoglobin. Conclusions Carbetocin is associated with a reduced use of additional oxytocics. It is unclear whether this may reduce rates of PPH and blood transfusions.